UCB Announces Regulatory Filings for Cimzia® (Certolizumab Pegol) to Treat Psoriatic Arthritis and Axial Spondyloarthritis
02:04 EST 20 Feb 2013 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
ATLANTA, Feb. 20, 2013 /PRNewswire/ -- UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia® (certolizumab...
Other Sources for this Article
More From BioPortfolio on "UCB Announces Regulatory Filings for Cimzia® (Certolizumab Pegol) to Treat Psoriatic Arthritis and Axial Spondyloarthritis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
